

References

4 Key Solid Tumor Therapy Objectives iSPCs Can Help Achieve

By Shubhranshu Gupta, Ph.D

1. <https://www.cancer.org/research/cancer-facts-statistics.html>
2. <https://doi.org/10.1186/s40779-025-00595-2>
3. <https://doi.org/10.1093/jncics/pkad040>
4. <https://doi.org/10.1186/s12929-023-00982-8>
5. <https://www.drugs.com/price-guide/tecelra>
6. <https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor>
7. <https://ashpublications.org/ashclinicalnews/news/4930/Are-CAR-T-Cell-Therapies-Worth-the-Costs>
8. <https://kffhealthnews.org/news/article/rural-americans-barriers-cancer-treatment/>
9. <https://doi.org/10.3389/fimmu.2024.1414264>
10. <https://doi.org/10.1186/s40164-024-00591-7>
11. <https://doi.org/10.1158/2159-8290.CD-18-0442>
12. <https://doi.org/10.1186/s13046-022-02327-z>
13. <https://www.who.int/publications/m/item/considerations-in-developing-a-regulatory-framework-for-human-cells-and-tissues-and-for-advanced-therapy-medicinal-products>
14. <https://doi.org/10.1038/s41420-024-01815-9>
15. <https://doi.org/10.1186/s12935-021-02407-8>
16. <https://doi.org/10.1186/s13046-023-02832-9>
17. <https://doi.org/10.3389/fimmu.2014.00614>
18. <https://doi.org/10.3390/ijms24087493>
19. <https://doi.org/10.1182/blood-2006-07-035972>
20. <https://doi.org/10.1182/blood-2023-188417>
21. <https://doi.org/10.1073/pnas.1920413117>
22. <https://doi.org/10.3389/fonc.2022.979154>
23. <https://doi.org/10.1182/blood.2019004500>
24. <https://doi.org/10.1126/science.aba7365>
25. <https://www.fatetherapeutics.com/pipeline/immuno-oncology-candidates/ft825/>
26. <https://doi.org/10.1038/mt.2013.185>
27. https://www.proteinatlas.org/ENSG00000141736-ERBB2/tissue#expression_summary
28. <https://doi.org/10.18632/oncotarget.17528>
29. <https://doi.org/10.1182/blood.2022018598>
30. https://www.blincyto.com/?gad_source=1&qclid=Cj0KCQjwkZm BhDrARIsAAEbX1F4La5LRwyufnNMWRS-ZPeQ8HfQTPLjivCtrFbZFrHRi985MtF0AMaAogjEALw_wcB&qclsrc=aw.ds

31. <https://doi.org/10.1080/19420862.2023.2183540>
 32. <https://doi.org/10.1038/s41598-021-93351-0>
 33. <https://doi.org/10.1158/1538-7445.AM2017-55>
 34. <https://doi.org/10.1186/s40364-021-00294-9>
 35. <https://doi.org/10.1182/blood.2022015956>
 36. <https://doi.org/10.1016/j.jbo.2020.100332>
 37. <https://doi.org/10.1038/s41587-019-0192-1>
 38. <https://doi.org/10.4110/in.2020.20.e9>
 39. <https://doi.org/10.1016/j.ccell.2019.12.014>
 40. <https://doi.org/10.3389/fimmu.2021.766220>
 41. <https://doi.org/10.1016/j.stem.2022.02.009>
 42. <https://doi.org/10.1186/s13046-021-02148-6>
 43. <https://doi.org/10.1186/s40164-020-00171-5>
 44. <https://doi.org/10.1182/blood-2018-10-881722>
 45. <https://notchtx.com/wp-content/uploads/2024/12/2024-11-18-ASH-Cytokine-v4ba.pdf>
 46. <https://doi.org/10.3390/ijerph191912366>
 47. <https://doi.org/10.5966/sctm.2013-0050>
 48. <https://www.bioprocessintl.com/facility-design-engineering/scalability-in-cell-and-gene-therapy-facilities-how-today-s-developers-are-preparing-for-tomorrow-s-commercial-success>
 49. <https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-new-preclinical-data-ft596-shelf>
 50. <https://doi.org/10.1016/j.bej.2025.109672>
 51. <https://www.ppd.com/wp-content/uploads/2020/11/Advanced-Therapies-Regulatory-Focus-2020.11.pdf>
 52. <https://www.fda.gov/media/166138/download>
 53. https://link.springer.com/chapter/10.1007/978-3-031-34567-8_14
 54. <https://www.patheon.com/us/en/insights-resources/blog/autologous-cell-therapy-manufacturing-challenges-and-best-practices.html>
 55. https://www.ema.europa.eu/en/documents/presentation/presentation-chemistry-manufacturing-and-control-cmc-development-and-manufacturing-challenges-steven-howe_en.pdf
 56. <https://doi.org/10.3390/ijms242316929>
 57. <https://doi.org/10.3389/fbioe.2022.1074990>
 58. <https://www.cellandgene.com/doc/this-digital-twin-approach-aims-to-optimize-atmp-production-0001>
-